Recursion Pharmaceuticals, A Aktie

Kaufen

Verkaufen

4,99 USD +0,60 USD +13,67 %

nachbörslich10:23:57

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Bei einem anderen Broker handeln Smartphone

Marktkap.1,75 Mrd. EUR

Div. Rendite0,00%

WKNA3CM1C

ISINUS75629V1044

SymbolRXRX

Recursion Pharmaceuticals, A Aktien News

Sortieren:Datum Meistgelesen

10.01.25ZacksDoes Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

21.12.24MotleyFoolIs Recursion Pharmaceuticals Stock a Millionaire Maker?

10.12.24BenzingaWhat's Going On With Recursion Pharmaceuticals Stock?

20.11.24GlobeNewswireRecursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

08.11.24finanzen.netRecursion Pharmaceuticals, A stellte Quartalsergebnis zum abgelaufenen Jahresviertel vor

07.11.24BenzingaA Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals

07.11.24ZacksRecursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates

02.11.24MotleyFoolIs Recursion Pharmaceuticals a Millionaire-Maker Stock?

01.11.24ZacksRecursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

30.10.24ZacksRecursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

26.10.24MotleyFool3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

24.10.24ZacksRecursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know

22.10.24GlobeNewswireRecursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

15.10.24ZacksRecursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know

15.10.24PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, ARC, RXRX on Behalf of Shareholders

15.10.24MotleyFoolDown 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

02.10.24ZacksRecursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

02.10.24GlobeNewswireRecursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

23.09.24ZacksRecursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

20.09.24MotleyFoolIs Recursion Pharmaceuticals Stock a Buy?

07.09.24finanzen.netIn Kauflaune

Cathie Wood setzt auf Biotech: ARK investiert in Zukunftstechnologien

06.09.24finanzen.netNach US-Arbeitsmarktdaten: DAX geht mit Verlusten ins Wochenende - letztlich 18.300 Punkte gerettet -- US-Börsen in Rot -- NVIDIA, Applied Digital, TMTG, Broadcom, QUALCOMM, Intel, Salesforce im Fokus

05.09.24finanzen.netVor US-Arbeitsmarktdaten: Dow Jones gibt letztlich nach -- DAX geht wenig bewegt aus dem Handel -- NIO mit Umsatzsprung -- HPE mit Rekordumsatz -- Intel, NVIDIA, Daimler Truck, Super Micro im Fokus

04.09.24BenzingaDecoding 6 Analyst Evaluations For Recursion Pharmaceuticals

03.09.24BenzingaWhy Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

03.09.24BenzingaRecursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On?

03.09.24GlobeNewswireRecursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

30.08.24MotleyFoolIs Recursion Pharmaceuticals a Warren Buffett Stock?

18.08.24MotleyFoolThe Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

17.08.24MotleyFoolIs Recursion Pharmaceuticals Stock a Buy?

11.08.24MotleyFoolIs Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

10.08.24finanzen.netRecursion Pharmaceuticals, A: Bilanz zum abgelaufenen Quartal

08.08.24BenzingaAI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

08.08.24ZacksRecursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

08.08.24GlobeNewswireRecursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

07.08.24finanzen.netAusblick: Recursion Pharmaceuticals, A stellt das Zahlenwerk zum vergangenen Quartal vor

06.08.24MotleyFoolIs Recursion Pharmaceuticals a Millionaire-Maker?

29.07.24ZacksRecursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why

27.07.24MotleyFoolDown About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

26.07.24ZacksWall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know

Recursion Pharmaceuticals, A News

Recursion Pharmaceuticals, A News: auf dieser Seite finden Sie alle Recursion Pharmaceuticals, A News und Nachrichten zur Recursion Pharmaceuticals, A Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Recursion Pharmaceuticals, A News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Recursion Pharmaceuticals, A News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.